Roivant Sciences Overview
Latest ROE for Roivant Sciences: -6.29% — see history and peer comparisons.
Get informed when a big investor buys or sells
+ Follow-6.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for ROIV is -6.29%. That is below the sector sector average of -5.68%. Investors often review this figure alongside Roivant Sciences's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, ROIV currently prints -6.29% for ROE, while the sector average sits near -5.68%. That is roughly 10.7% below the sector mean. Large gaps often invite a closer look at Roivant Sciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Roivant Sciences converts resources into returns. At -6.29%, ROIV may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting ROIV's ROE (-6.29%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
